COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

CPTAC Launches Proteomics Data Portal

The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) announces the launch of the CPTAC Data Portal. The Data Portal hosts all the data that is currently being produced by the consortium with additional historic data from CPTAC 1. The total amount of hosted data exceeds over 500 GB of RAW data in over 800 files.

Currently, the initial raw data files from the CPTAC Due Diligence Studies are available for download. These data include the characterization of the proteome and phosphoproteome in experiments that demonstrate the capabilities of each of the mass spectrometry platforms that will be used to analyze genomically characterized biospecimens from sources including The Cancer Genome Atlas Project. Model systems were used to address issues regarding the stability of proteins and their post-translational modifications in excised tissues during sample accruement and handling prior to mass spectrometry analyses, and the detection of tumor-specific proteomic signatures.

CPTAC requests that data users abide by the data sharing principles established at the Fort Lauderdale (2003) and Amsterdam (2008) meetings. “Responsible use” is defined as allowing the data producers to have the opportunity to publish the initial global analyses of large-scale genomic and proteomic data within a reasonable period of time. Agreeing to abide by these principles and the CPTAC Publication Guidelines is required to gain access to the CPTAC data.

CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows.